

David J Greenblatt

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9440794/david-j-greenblatt-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

641
papers

29,388
citations

89
h-index

133
g-index

726
ext. papers

31,714
ext. citations

5.2
avg, IF

6.83
L-index

#	Paper	IF	Citations
641	Slow Accumulation and Elimination of Diazepam and Its Active Metabolite With Extended Treatment in the Elderly. <i>Journal of Clinical Pharmacology</i> , 2021 , 61, 193-203	2.9	1
640	Mechanism of dasabuvir inhibition of acetaminophen glucuronidation. <i>Journal of Pharmacy and Pharmacology</i> , 2021 ,	4.8	1
639	Effect of lipophilicity on drug distribution and elimination: Influence of obesity. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 3197-3205	3.8	9
638	Brexipiprazole Pharmacokinetics in CYP2D6 Poor Metabolizers: Using Physiologically Based Pharmacokinetic Modeling to Optimize Time to Effective Concentrations. <i>Journal of Clinical Pharmacology</i> , 2021 ,	2.9	2
637	Impact of Obesity on Brexpiprazole Pharmacokinetics: Proposal for Improved Initiation of Treatment. <i>Journal of Clinical Pharmacology</i> , 2021 ,	2.9	1
636	The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator. <i>Clinical Pharmacology in Drug Development</i> , 2020 , 9, 1015-1024	2.3	2
635	Comment on the Next Chapter of the Journal of Clinical Psychopharmacology. <i>Journal of Clinical Psychopharmacology</i> , 2020 , 40, 528	1.7	
634	Methadone Disposition: Implementing Lessons Learned. <i>Journal of Clinical Pharmacology</i> , 2019 , 59, 1044-1048	2.1048	10
633	Erythromycin acts through the ghrelin receptor to attenuate inflammatory responses in chondrocytes and maintain joint integrity. <i>Biochemical Pharmacology</i> , 2019 , 165, 79-90	6	3
632	Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl. <i>Journal of Pharmacy and Pharmacology</i> , 2019 , 71, 982-987	4.8	6
631	Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years Old. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	2
630	Public Health Risk of Designer Psychotropic Drugs: Should PHASE Be Phased In?. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 1175-1176	6.1	
629	Zolpidem and Gender: Are Women Really At Risk?. <i>Journal of Clinical Psychopharmacology</i> , 2019 , 39, 189-199	1.199	22
628	Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	5
627	Resveratrol glucuronidation in vitro: potential implications of inhibition by probenecid. <i>Journal of Pharmacy and Pharmacology</i> , 2019 , 71, 371-378	4.8	4
626	Therapeutic Drug Monitoring of Antidepressants. <i>Handbook of Experimental Pharmacology</i> , 2019 , 250, 115-133	3.2	8
625	Opportunistic Journals in the Clinical Pharmacology Space: A Policy Statement From the Publications and Public Policy Committees of the American College of Clinical Pharmacology. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 567-571	2.9	3

624	Inhibitory effects of sulfonylureas and non-steroidal anti-inflammatory drugs on in vitro metabolism of canagliflozin in human liver microsomes. <i>Biopharmaceutics and Drug Disposition</i> , 2018 , 39, 135-142	1.7	1
623	Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study. <i>Clinical Therapeutics</i> , 2018 , 40, 64-73	3.5	8
622	Opportunistic Journals in the Clinical Pharmacology Space: A Policy Statement From the Publications and Public Policy Committees of the American College of Clinical Pharmacology. <i>Clinical Pharmacology in Drug Development</i> , 2018 , 7, 353-357	2.3	0
621	Vortioxetine Disposition in Obesity: Potential Implications for Patient Safety. <i>Journal of Clinical Psychopharmacology</i> , 2018 , 38, 172-179	1.7	8
620	In vitro inhibition of human UGT isoforms by ritonavir and cobicistat. <i>Xenobiotica</i> , 2018 , 48, 764-769	2	9
619	Persistence of a Posaconazole-Mediated Drug-Drug Interaction With Ranolazine After Cessation of Posaconazole Administration: Impact of Obesity and Implications for Patient Safety. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 1436-1442	2.9	9
618	Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole: Impact of Obesity, and Implications for Patient Safety. <i>Journal of Clinical Psychopharmacology</i> , 2018 , 38, 289-295	1.7	13
617	Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 533-540	2.9	26
616	Mechanisms and Consequences of Drug-Drug Interactions. <i>Clinical Pharmacology in Drug Development</i> , 2017 , 6, 118-124	2.3	14
615	Inhibition of human cytochromes P450 in vitro by ritonavir and cobicistat. <i>Journal of Pharmacy and Pharmacology</i> , 2017 , 69, 1786-1793	4.8	23
614	Mechanism of in-vitro inhibition of UGT1A1 by paritaprevir. <i>Journal of Pharmacy and Pharmacology</i> , 2017 , 69, 1794-1801	4.8	7
613	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. <i>Journal of Pharmacy and Pharmacology</i> , 2017 , 69, 1762-1772 ⁸	4.8	24
612	Inhibitory Effects of Selected Antituberculosis Drugs on Common Human Hepatic Cytochrome P450 and UDP-glucuronosyltransferase Enzymes. <i>Drug Metabolism and Disposition</i> , 2017 , 45, 1035-1043 ⁴	4	13
611	Race, Gender, and Genetic Polymorphism Contribute to Variability in Acetaminophen Pharmacokinetics, Metabolism, and Protein-Adduct Concentrations in Healthy African-American and European-American Volunteers. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017 , 320, 131-140	4.7	35
610	Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination. <i>Journal of Pharmacy and Pharmacology</i> , 2017 , 69, 82-88	4.8	6
609	Pharmacokinetics and Pharmacodynamics for Medical Students: A Proposed Course Outline. <i>Journal of Clinical Pharmacology</i> , 2016 , 56, 1180-95	2.9	7
608	A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression. <i>Neurology</i> , 2016 , 86, 1474-81	6.5	51
607	Evidence-based choice of ritonavir as index CYP3A inhibitor in drug-drug interaction studies. <i>Journal of Clinical Pharmacology</i> , 2016 , 56, 152-6	2.9	14

606	Use of Antipsychotics for the Treatment of Behavioral Symptoms of Dementia. <i>Journal of Clinical Pharmacology</i> , 2016 , 56, 1048-57	2.9	18
605	Ketoconazole-Associated Liver Injury in Drug-Drug Interaction Studies in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2016 , 56, 1196-202	2.9	6
604	Body Size Changes Among National Collegiate Athletic Association New England Division III Football Players, 1956-2014: Comparison With Age-Matched Population Controls. <i>Journal of Athletic Training</i> , 2016 , 51, 373-81	4	6
603	Altered drug disposition following bariatric surgery: a research challenge. <i>Clinical Pharmacokinetics</i> , 2015 , 54, 573-9	6.2	27
602	Adverse performance effects of acute lorazepam administration in elderly long-term users: pharmacokinetic and clinical predictors. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015 , 56, 129-35	5.5	15
601	Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 1076-85	3.8	18
600	Preclinical Rodent Toxicity Studies for Long Term Use of Ceftriaxone. <i>Toxicology Reports</i> , 2015 , 2, 1396-1403	4.8	7
599	Inhibition of 2-methoxyestradiol glucuronidation by probenecid. <i>Journal of Pharmacy and Pharmacology</i> , 2015 , 67, 1585-92	4.8	7
598	Regression and Correlation. <i>Clinical Pharmacology in Drug Development</i> , 2015 , 4, 161-2	2.3	3
597	Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 342-50	3.8	52
596	Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis. <i>Journal of Clinical Pharmacology</i> , 2014 , 54, 1180-7	2.9	12
595	Candidate gene polymorphisms in patients with acetaminophen-induced acute liver failure. <i>Drug Metabolism and Disposition</i> , 2014 , 42, 28-32	4	45
594	In vitro prediction of clinical drug interactions with CYP3A substrates: we are not there yet. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 95, 133-5	6.1	16
593	Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , 2014 , 13, 1083-1091	24.1	152
592	Liver injury associated with ketoconazole: review of the published evidence. <i>Journal of Clinical Pharmacology</i> , 2014 , 54, 1321-9	2.9	45
591	Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration. <i>Journal of Clinical Pharmacology</i> , 2014 , 54, 282-90	2.9	62
590	Pharmacokinetics of zolpidem from sublingual zolpidem tartrate tablets in healthy elderly versus non-elderly subjects. <i>Drugs and Aging</i> , 2014 , 31, 731-6	4.7	10
589	Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 4145-52	5.9	15

588	Characterization of cognitive dysfunction in Sjögren's syndrome patients. <i>Clinical Rheumatology</i> , 2014 , 33, 511-21	3.9	11
587	Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2013 , 75, 450-62	3.8	51
586	Comparison of pharmacokinetic profiles of zolpidem buffered sublingual tablet and zolpidem oral immediate-release tablet: results from a single-center, single-dose, randomized, open-label crossover study in healthy adults. <i>Clinical Therapeutics</i> , 2013 , 35, 604-11	3.5	33
585	Grapefruit-medication interactions. <i>Cmaj</i> , 2013 , 185, 507	3.5	4
584	The UDP-glucuronosyltransferase (UGT) 1A polymorphism c.2042C>G (rs8330) is associated with increased human liver acetaminophen glucuronidation, increased UGT1A exon 5a/5b splice variant mRNA ratio, and decreased risk of unintentional acetaminophen-induced acute liver failure. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013 , 345, 297-307	4.7	60
583	Effect of blueberry juice on clearance of buspirone and flurbiprofen in human volunteers. <i>British Journal of Clinical Pharmacology</i> , 2013 , 75, 1041-52	3.8	11
582	Influence of food on pharmacokinetics of zolpidem from fast dissolving sublingual zolpidem tartrate tablets. <i>Journal of Clinical Pharmacology</i> , 2013 , 53, 1194-8	2.9	7
581	Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. <i>PLoS ONE</i> , 2013 , 8, e61177	3.7	79
580	Evidence for epigenetic regulation of UGT1A1 protein expression and activity in healthy human livers. <i>FASEB Journal</i> , 2013 , 27, 270.5	0.9	
579	Pomegranate juice and pomegranate extract do not impair oral clearance of flurbiprofen in human volunteers: divergence from in vitro results. <i>Clinical Pharmacology and Therapeutics</i> , 2012 , 92, 651-7	6.1	21
578	Zolpidem for insomnia. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 879-93	4	154
577	Mechanism-based inhibition of human cytochrome P450-3A activity by grapefruit hybrids having low furanocoumarin content. <i>Xenobiotica</i> , 2012 , 42, 1163-9	2	12
576	From disordered eating to addiction: the "food drug" in bulimia nervosa. <i>Journal of Clinical Psychopharmacology</i> , 2012 , 32, 376-89	1.7	40
575	Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012 , 8, 1609-18	5.5	15
574	Mechanism of cytochrome P450-3A inhibition by ketoconazole. <i>Journal of Pharmacy and Pharmacology</i> , 2011 , 63, 214-21	4.8	68
573	Translocase of outer mitochondrial membrane 40 homolog (TOMM40) poly-T length modulates lorazepam-related cognitive toxicity in healthy APOE ε-negative elderly. <i>Journal of Clinical Psychopharmacology</i> , 2011 , 31, 544-6	1.7	6
572	Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. <i>British Journal of Clinical Pharmacology</i> , 2011 , 72, 434-41	3.8	25
571	Pharmacokinetic profile of SKP-1041, a modified release formulation of zaleplon. <i>Biopharmaceutics and Drug Disposition</i> , 2011 , 32, 489-97	1.7	3

570	Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2933-40	2.2	81
569	The effect of grapefruit juice on drug disposition. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011 , 7, 267-86	5.5	137
568	Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 3527-33	5.9	19
567	Clinical Pharmacology and Therapeutics of Antidepressants 2011 , 33-124		5
566	Introduction to Drug-Drug Interactions 2011 , 1-10		5
565	Relationship between plasma protease inhibitor concentrations and lipid elevations in HIV patients on a double-boosted protease inhibitor regimen (saquinavir/lopinavir/ritonavir). <i>Journal of Clinical Pharmacology</i> , 2010 , 50, 392-400	2.9	4
564	Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro. <i>Xenobiotica</i> , 2010 , 40, 713-20	2	28
563	Effect of obesity on the pharmacokinetics of drugs in humans. <i>Clinical Pharmacokinetics</i> , 2010 , 49, 71-87	6.2	482
562	Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin. <i>Journal of Pharmacy and Pharmacology</i> , 2010 , 55, 1707-1707	4.8	
561	A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2010 , 11, 508-13		27
560	Mechanisms and Consequences of Drug-Drug Interactions 2010 , 1		
559	Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate. <i>Biopharmaceutics and Drug Disposition</i> , 2010 , 31, 72-81	1.7	4
558	Pharmacokinetic Determinants of the Clinical Effects of Benzodiazepine Agonist Hypnotics 2010 , 95-118		5
557	Clinical Studies of Drug-Drug Interactions: Design and Interpretation 2010 , 625-649		19
556	Analysis of drug interactions involving fruit beverages and organic anion-transporting polypeptides. <i>Journal of Clinical Pharmacology</i> , 2009 , 49, 1403-7	2.9	46
555	Role of NADPH-cytochrome P450 reductase and cytochrome-b5/NADH-b5 reductase in variability of CYP3A activity in human liver microsomes. <i>Drug Metabolism and Disposition</i> , 2009 , 37, 90-6	4	33
554	Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. <i>British Journal of Clinical Pharmacology</i> , 2009 , 68, 721-30	3.8	51
553	Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase. <i>British Journal of Clinical Pharmacology</i> , 2009 , 68, 920-7	3.8	32

552	Propofol clearance and volume of distribution are increased in patients with major burns. <i>Journal of Clinical Pharmacology</i> , 2009 , 49, 768-72	2.9	11
551	Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem. <i>Clinical Pharmacology and Therapeutics</i> , 2009 , 85, 644-50	6.1	23
550	The absence of an interaction between warfarin and cranberry juice: a randomized, double-blind trial. <i>Journal of Clinical Pharmacology</i> , 2009 , 49, 824-30	2.9	36
549	Influence of fruit juices on drug disposition: discrepancies between in vitro and clinical studies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008 , 4, 381-93	5.5	53
548	Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. <i>Journal of Clinical Pharmacology</i> , 2008 , 48, 1032-40	2.9	36
547	Drug-Drug Interactions, Second Edition 2008 ,		6
546	Pharmacologic consideration for the use of antiretroviral agents in the elderly. <i>Journal of Clinical Pharmacology</i> , 2008 , 48, 1212-25	2.9	22
545	Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. <i>Journal of Clinical Pharmacology</i> , 2008 , 48, 1350-5	2.9	68
544	Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008 , 49, 358-68	3.1	29
543	Chapter 11:The CYP3 Family. <i>Issues in Toxicology</i> , 2008 , 354-383	0.3	15
542	Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells. <i>Journal of Pharmacy and Pharmacology</i> , 2007 , 59, 947-53	4.8	39
541	Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice. <i>Journal of Clinical Pharmacology</i> , 2007 , 47, 286-94	2.9	62
540	Role of CYP3A and CYP2E1 in alcohol-mediated increases in acetaminophen hepatotoxicity: comparison of wild-type and Cyp2e1(-/-) mice. <i>Drug Metabolism and Disposition</i> , 2007 , 35, 1223-31	4	46
539	Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 28-34	1.7	55
538	Age and gender effects on the pharmacokinetics and pharmacodynamics of ramelteon, a hypnotic agent acting via melatonin receptors MT1 and MT2. <i>Journal of Clinical Pharmacology</i> , 2007 , 47, 485-96	2.9	53
537	Fentanyl clearance and volume of distribution are increased in patients with major burns. <i>Journal of Clinical Pharmacology</i> , 2007 , 47, 674-80	2.9	34
536	Dose-dependent retrograde facilitation of verbal memory in healthy elderly after acute oral lorazepam administration. <i>Psychopharmacology</i> , 2006 , 185, 487-94	4.7	6
535	The effect of chronic lorazepam administration in aging mice. <i>Brain Research</i> , 2006 , 1118, 13-24	3.7	5

534	Acute zolpidem administration produces pharmacodynamic and receptor occupancy changes at similar doses. <i>Pharmacology Biochemistry and Behavior</i> , 2006 , 83, 21-7	3.9	16
533	Apparent active transport of MDMA is not mediated by P-glycoprotein: a comparison with MDCK and Caco-2 monolayers. <i>Biopharmaceutics and Drug Disposition</i> , 2006 , 27, 219-27	1.7	15
532	Factors influencing midazolam hydroxylation activity in human liver microsomes. <i>Drug Metabolism and Disposition</i> , 2006 , 34, 1198-207	4	46
531	Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. <i>Journal of Clinical Pharmacology</i> , 2006 , 46, 1469-80	2.9	48
530	The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. <i>Drug Metabolism and Disposition</i> , 2006 , 34, 1220-8	4	67
529	Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers. <i>Journal of Clinical Pharmacology</i> , 2006 , 46, 567-76	2.9	29
528	Balancing efficacy and safety in the use of oral sedation in dental outpatients. <i>Journal of the American Dental Association</i> , 2006 , 137, 502-13	1.9	28
527	Human pregnane X receptor: genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity. <i>Journal of Clinical Pharmacology</i> , 2006 , 46, 1356-69	2.9	17
526	Pharmacokinetic determinants of hypnotic drug action: The art and science of controlling release. <i>Sleep Medicine</i> , 2006 , 7, S10-S14	4.6	2
525	In vitro interactions of water-soluble garlic components with human cytochromes p450. <i>Journal of Nutrition</i> , 2006 , 136, 806S-809S	4.1	24
524	Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. <i>Journal of Clinical Pharmacology</i> , 2006 , 46, 214-21	2.9	41
523	Pharmacologic management of dental anxiety: conscious versus unconscious sedation. <i>Journal of Clinical Psychopharmacology</i> , 2006 , 26, 1-3	1.7	5
522	Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials. <i>Journal of Clinical Pharmacology</i> , 2006 , 46, 179-92	2.9	45
521	Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 79, 125-33	6.1	67
520	Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 79, 243-54	6.1	56
519	Simple and rapid liquid chromatography method for determination of efavirenz in plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006 , 835, 131-5	3.2	35
518	A Randomized, Double-Blind Trial of the Interaction between Cranberry Juice and Warfarin.. <i>Blood</i> , 2006 , 108, 4125-4125	2.2	
517	Identification of Human Cd8+ and Cd4+ Lymphocytes with Unique Drug Resistance Activity by Imaging the Drug Transport Kinetics at the Single Cell Resolution.. <i>Blood</i> , 2006 , 108, 3894-3894	2.2	

516	Interaction of warfarin with drugs, natural substances, and foods. <i>Journal of Clinical Pharmacology</i> , 2005 , 45, 127-32	2.9	124
515	Clonazepam pharmacokinetics: comparison of subcutaneous microsphere injection with multiple-dose oral administration. <i>Journal of Clinical Pharmacology</i> , 2005 , 45, 1288-93	2.9	7
514	The influence of age and sex on the clearance of cytochrome P450 3A substrates. <i>Clinical Pharmacokinetics</i> , 2005 , 44, 33-60	6.2	215
513	Hyperforin plasma level as a marker of treatment adherence in the National Institutes of Health Hypericum Depression Trial. <i>Journal of Clinical Psychopharmacology</i> , 2005 , 25, 243-9	1.7	11
512	Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers. <i>Journal of Clinical Pharmacology</i> , 2005 , 45, 529-37	2.9	20
511	Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 77, 373-87	6.1	101
510	UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005 , 313, 1340-6	4.7	88
509	Pharmacokinetics and pharmacodynamics of single-dose triazolam: electroencephalography compared with the Digit-Symbol Substitution Test. <i>British Journal of Clinical Pharmacology</i> , 2005 , 60, 244-8	3.8	27
508	Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics. <i>British Journal of Clinical Pharmacology</i> , 2005 , 60, 486-93	3.8	42
507	UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver. <i>Hepatology</i> , 2005 , 42, 448-57	11.2	68
506	Cortisol response to diazepam: its relationship to age, dose, duration of treatment, and presence of generalized anxiety disorder. <i>Psychopharmacology</i> , 2005 , 178, 1-8	4.7	39
505	Sex-related elevation in cortisol during chronic treatment with alprazolam associated with enhanced cognitive performance. <i>Psychopharmacology</i> , 2005 , 182, 414-9	4.7	6
504	Role of the nuclear receptor pregnane X receptor in acetaminophen hepatotoxicity. <i>Drug Metabolism and Disposition</i> , 2005 , 33, 1827-36	4	30
503	Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. <i>Drug Metabolism and Disposition</i> , 2005 , 33, 764-70	4	122
502	UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: I. Identification of polymorphisms in the 5' regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005 , 313, 1331-9	4.7	47
501	Inhibition of human cytochromes P450 by components of Ginkgo biloba. <i>Journal of Pharmacy and Pharmacology</i> , 2004 , 56, 1039-44	4.8	114
500	Phenacetin and chlorzoxazone biotransformation in aging male Fischer 344 rats. <i>Journal of Pharmacy and Pharmacology</i> , 2004 , 56, 819-25	4.8	11
499	Ethanol inhibits in-vitro metabolism of nifedipine, triazolam and testosterone in human liver microsomes. <i>Journal of Pharmacy and Pharmacology</i> , 2004 , 56, 963-6	4.8	1

498	Effect of age on in vitro triazolam biotransformation in male human liver microsomes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004 , 308, 874-9	4.7	25
497	Interaction of triazolam and ketoconazole in P-glycoprotein-deficient mice. <i>Drug Metabolism and Disposition</i> , 2004 , 32, 800-4	4	34
496	Evaluation of 5-hydroxytryptophol and other endogenous serotonin (5-hydroxytryptamine) analogs as substrates for UDP-glucuronosyltransferase 1A6. <i>Drug Metabolism and Disposition</i> , 2004 , 32, 862-9	4	44
495	The effect of age on P-glycoprotein expression and function in the Fischer-344 rat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004 , 309, 730-6	4.7	30
494	UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004 , 310, 656-65	4.7	94
493	Age-related differences in CYP3A expression and activity in the rat liver, intestine, and kidney. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004 , 309, 720-9	4.7	48
492	Role of CYP3A enzymes in the biotransformation of triazolam in rat liver. <i>Xenobiotica</i> , 2004 , 34, 463-71	2	3
491	Levothyroxine up-regulates P-glycoprotein independent of the pregnane X receptor. <i>Drug Metabolism and Disposition</i> , 2004 , 32, 779-82	4	42
490	Interdose elevation in plasma cortisol during chronic treatment with alprazolam but not lorazepam in the elderly. <i>Neuropsychopharmacology</i> , 2004 , 29, 605-11	8.7	9
489	Effects of acute lorazepam administration on aminergic activity in normal elderly subjects: relationship to performance effects and apolipoprotein genotype. <i>Neurochemical Research</i> , 2004 , 29, 1391-8	4.6	4
488	Baseline plasma GABA: its relationship to the adverse effects of acute lorazepam administration on cognition in the elderly. <i>Neurochemical Research</i> , 2004 , 29, 2311-5	4.6	0
487	Interactions of tamoxifen, N-desmethyldtamoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A. <i>Biopharmaceutics and Drug Disposition</i> , 2004 , 25, 283-9	1.7	25
486	Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 76, 467-79	6.1	61
485	Kinetics and EEG effects of midazolam during and after 1-minute, 1-hour, and 3-hour intravenous infusions. <i>Journal of Clinical Pharmacology</i> , 2004 , 44, 605-11	2.9	23
484	Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats. <i>Xenobiotica</i> , 2004 , 34, 133-50	2	66
483	Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia. <i>Journal of Clinical Pharmacology</i> , 2004 , 44, 1173-84	2.9	13
482	Analysis of generic antiretroviral formulations manufactured in India. <i>Aids</i> , 2004 , 18, 1482-4	3.5	7
481	Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. <i>Pharmacogenetics and Genomics</i> , 2004 , 14, 225-38		173

480	Clinical Pharmacology and Therapeutics of Antidepressants 2004 , 33-117		4
479	Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin. <i>Journal of Pharmacy and Pharmacology</i> , 2003 , 55, 1229-39	4.8	19
478	Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir. <i>Journal of Pharmacy and Pharmacology</i> , 2003 , 55, 381-6	4.8	23
477	The effect of age on sildenafil biotransformation in rat and mouse liver microsomes. <i>Drug Metabolism and Disposition</i> , 2003 , 31, 1306-9	4	12
476	Drug metabolism and drug interactions: application and clinical value of in vitro models. <i>Current Drug Metabolism</i> , 2003 , 4, 423-59	3.5	139
475	Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. <i>Journal of Clinical Pharmacology</i> , 2003 , 43, 414-22	2.9	45
474	Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital. <i>Journal of Clinical Psychopharmacology</i> , 2003 , 23, 269-80	1.7	20
473	Imipramine and buspirone in patients with panic disorder who are discontinuing long-term benzodiazepine therapy. <i>Journal of Clinical Psychopharmacology</i> , 2003 , 23, 505-8	1.7	14
472	Rapid assessment of P-glycoprotein inhibition and induction in vitro. <i>Pharmaceutical Research</i> , 2003 , 20, 1177-83	4.5	69
471	Validation of serotonin (5-hydroxytryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6. <i>Drug Metabolism and Disposition</i> , 2003 , 31, 133-9	4	100
470	Human cytochromes mediating gepirone biotransformation at low substrate concentrations. <i>Biopharmaceutics and Drug Disposition</i> , 2003 , 24, 87-94	1.7	11
469	Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 74, 121-9	6.1	125
468	Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. <i>British Journal of Clinical Pharmacology</i> , 2003 , 56, 297-304	3.8	74
467	Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. <i>Drug Metabolism and Disposition</i> , 2003 , 31, 289-93	4	245
466	In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. <i>Drug Metabolism and Disposition</i> , 2003 , 31, 938-44	4	210
465	Clinically important drug interactions with zopiclone, zolpidem and zaleplon. <i>CNS Drugs</i> , 2003 , 17, 513-38	3.7	71
464	Evaluation of 3-Azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. <i>Drug Metabolism and Disposition</i> , 2003 , 31, 1125-33	4	220
463	Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. <i>Aids</i> , 2003 , 17, 1092-4	3.5	24

462	Evaluation of Supermix as an in vitro model of human liver microsomal drug metabolism. <i>Biopharmaceutics and Drug Disposition</i> , 2002 , 23, 183-90	1.7	10
461	Effect of zolpidem on human cytochrome P450 activity, and on transport mediated by P-glycoprotein. <i>Biopharmaceutics and Drug Disposition</i> , 2002 , 23, 361-7	1.7	25
460	Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. <i>Pharmaceutical Research</i> , 2002 , 19, 1038-45	4.5	101
459	In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002 , 302, 1228-37	4.7	90
458	Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. <i>Drug Metabolism and Disposition</i> , 2002 , 30, 1257-65	4	148
457	In vitro biotransformation of sildenafil (Viagra) in the male rat: the role of CYP2C11. <i>Drug Metabolism and Disposition</i> , 2002 , 30, 655-7	4	20
456	Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. <i>Drug Metabolism and Disposition</i> , 2002 , 30, 1441-5	4	82
455	Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques. <i>Journal of Clinical Pharmacology</i> , 2002 , 42, 376-382	2.9	30
454	Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. <i>Journal of Clinical Pharmacology</i> , 2002 , 42, 1269-74	2.9	71
453	Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques 2002 , 42, 376		11
452	Zolpidem pharmacokinetic properties in young females: influence of smoking and oral contraceptive use. <i>Journal of Clinical Pharmacology</i> , 2002 , 42, 1142-6	2.9	18
451	Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. <i>Journal of Clinical Pharmacology</i> , 2002 , 42, 376-82	2.9	14
450	Molecular and pharmacokinetic evaluation of rat hepatic and gastrointestinal cytochrome p450 induction by tamoxifen. <i>Pharmacology</i> , 2001 , 63, 210-9	2.3	14
449	Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. <i>European Journal of Clinical Pharmacology</i> , 2001 , 57, 31-6	2.8	87
448	Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. <i>Journal of Pharmaceutical Sciences</i> , 2001 , 90, 1829-37	3.9	99
447	Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. <i>British Journal of Pharmacology</i> , 2001 , 134, 1601-8	8.6	135
446	Pharmacodynamic and receptor binding changes during chronic lorazepam administration. <i>Pharmacology Biochemistry and Behavior</i> , 2001 , 69, 1-8	3.9	22
445	Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. <i>Journal of Clinical Pharmacology</i> , 2001 , 41, 1149-79	2.9	222

444	Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. <i>Journal of Clinical Pharmacology</i> , 2001 , 41, 85-91	2.9	88
443	P-glycoprotein interactions of nefazodone and trazodone in cell culture. <i>Journal of Clinical Pharmacology</i> , 2001 , 41, 708-14	2.9	34
442	A benzodiazepine mood effect scale: reliability and validity determined for alcohol-dependent subjects and adults with a parental history of alcoholism. <i>American Journal of Drug and Alcohol Abuse</i> , 2001 , 27, 339-47	3.7	4
441	Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. <i>Journal of Clinical Pharmacology</i> , 2001 , 41, 1043-54	2.9	50
440	Cognitive toxicity of drugs used in the elderly. <i>Dialogues in Clinical Neuroscience</i> , 2001 , 3, 181-90	5.7	6
439	Unusually low clearance of two CYP3A substrates, alprazolam and trazodone, in a volunteer subject with wild-type CYP3A4 promoter region. <i>Journal of Clinical Pharmacology</i> , 2000 , 40, 200-4	2.9	3
438	Kinetics and dynamics of lorazepam during and after continuous intravenous infusion. <i>Critical Care Medicine</i> , 2000 , 28, 2750-7	1.4	32
437	The influence of the menstrual cycle on triazolam and indocyanine green pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , 2000 , 40, 739-44	2.9	12
436	Differential impairment of triazolam and zolpidem clearance by ritonavir. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000 , 24, 129-36	3.1	43
435	Methodologies to study the induction of rat hepatic and intestinal cytochrome P450 3A at the mRNA, protein, and catalytic activity level. <i>Journal of Pharmacological and Toxicological Methods</i> , 2000 , 43, 41-54	1.7	37
434	Alprazolam-ritonavir interaction: implications for product labeling. <i>Clinical Pharmacology and Therapeutics</i> , 2000 , 67, 335-41	6.1	94
433	Differential Impairment of Triazolam and Zolpidem Clearance by Ritonavir. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000 , 24, 129-136	3.1	59
432	Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy. <i>American Journal of Psychiatry</i> , 2000 , 157, 1973-9	11.9	59
431	In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. <i>Biological Psychiatry</i> , 2000 , 47, 655-61	7.9	50
430	Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. <i>Clinical Pharmacokinetics</i> , 2000 , 38, 111-80	6.2	396
429	Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. <i>Aids</i> , 2000 , 14, 1287-9	3.5	67
428	Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam. <i>Journal of Clinical Psychopharmacology</i> , 2000 , 20, 338-46	1.7	11
427	Lack of effect of sertraline on the pharmacokinetics of alprazolam. <i>Journal of Clinical Psychopharmacology</i> , 2000 , 20, 585-6	1.7	7

426	A comparative pharmacokinetic and dynamic evaluation of alprazolam sustained-release, bromazepam, and lorazepam. <i>Journal of Clinical Psychopharmacology</i> , 2000 , 20, 628-35	1.7	14
425	Molecular genetic basis for deficient acetaminophen glucuronidation by cats: UGT1A6 is a pseudogene, and evidence for reduced diversity of expressed hepatic UGT1A isoforms. <i>Pharmacogenetics and Genomics</i> , 2000 , 10, 355-69		147
424	Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2000 , 293, 435-43	4.7	81
423	In situ hybridization histochemistry as a method to assess GABA(A) receptor subunit mRNA expression following chronic alprazolam administration. <i>Journal of Psychopharmacology</i> , 1999 , 13, 211-8 ^{4.6}		7
422	Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. <i>British Journal of Clinical Pharmacology</i> , 1999 , 48, 89-97	3.8	123
421	Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. <i>Clinical Pharmacology and Therapeutics</i> , 1999 , 66, 461-71	6.1	212
420	Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. <i>Psychopharmacology</i> , 1999 , 145, 113-22	4.7	66
419	Unchanged cytochrome P450 3A (CYP3A) expression and metabolism of midazolam, triazolam, and dexamethasone in mdr(-/-) mouse liver microsomes. <i>Biochemical Pharmacology</i> , 1999 , 57, 1227-32	6	27
418	Lorazepam attenuates the behavioral effects of dizocilpine. <i>Pharmacology Biochemistry and Behavior</i> , 1999 , 62, 103-10	3.9	10
417	O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. <i>Neuropsychopharmacology</i> , 1999 , 20, 480-90	8.7	129
416	Inhibition of human cytochrome P450 isoforms in vitro by zafirlukast. <i>Biopharmaceutics and Drug Disposition</i> , 1999 , 20, 385-8	1.7	26
415	Pharmacokinetics and electroencephalographic effects of ketoconazole in the rat. <i>Biopharmaceutics and Drug Disposition</i> , 1999 , 20, 49-52	1.7	6
414	Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. <i>Biological Psychiatry</i> , 1999 , 46, 839-49	7.9	69
413	Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine. <i>Drug Metabolism Reviews</i> , 1999 , 31, 545-60	7	29
412	Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. <i>Journal of Clinical Pharmacology</i> , 1999 , 39, 567-77	2.9	67
411	Population pharmacokinetics of methylphenidate in children with attention-deficit hyperactivity disorder. <i>Journal of Clinical Pharmacology</i> , 1999 , 39, 775-85	2.9	35
410	Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. <i>Journal of Clinical Psychopharmacology</i> , 1999 , 19, 23S-35S	1.7	71
409	Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. <i>Journal of Pharmacy and Pharmacology</i> , 1998 , 50, 997-1004	4.8	78

408	Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 64, 661-71	6.1	73
407	Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 64, 553-61	6.1	107
406	Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 64, 237-47	6.1	103
405	Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 64, 278-85	6.1	83
404	Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach. <i>Journal of Pharmaceutical Sciences</i> , 1998 , 87, 845-53	3.9	41
403	Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. <i>Journal of Pharmaceutical Sciences</i> , 1998 , 87, 1184-9	3.9	53
402	Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity. <i>Journal of Pharmaceutical Sciences</i> , 1998 , 87, 1502-7	3.9	58
401	Analysis of ritonavir in plasma/serum and tissues by high-performance liquid chromatography. <i>Journal of Pharmacological and Toxicological Methods</i> , 1998 , 40, 235-9	1.7	20
400	In vitro approaches to predicting drug interactions in vivo. <i>Biochemical Pharmacology</i> , 1998 , 55, 113-22	6	176
399	Pharmacokinetics and pharmacodynamics of diphenhydramine 25 mg in young and elderly volunteers. <i>Journal of Clinical Pharmacology</i> , 1998 , 38, 603-9	2.9	36
398	Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. <i>Journal of Clinical Pharmacology</i> , 1998 , 38, 112-21	2.9	125
397	Single-dose pharmacokinetics and pharmacodynamics of alprazolam in elderly and young subjects. <i>Journal of Clinical Pharmacology</i> , 1998 , 38, 14-21	2.9	23
396	Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. <i>Journal of Clinical Pharmacology</i> , 1998 , 38, 106-11	2.9	193
395	The maturation of clinical pharmacology: recognizing the contributions of Dr. Louis Lasagna. <i>Journal of Clinical Pharmacology</i> , 1998 , 38, 572-4	2.9	3
394	Nefazodone in major depression: adjunctive benzodiazepine therapy and tolerability. <i>Journal of Clinical Psychopharmacology</i> , 1998 , 18, 145-53	1.7	13
393	ApoE-epsilon 4 allele and susceptibility to drug-induced memory impairment in the elderly. <i>Journal of Clinical Psychopharmacology</i> , 1998 , 18, 179-81	1.7	7
392	Alprazolam is another substrate for human cytochrome P450-3A isoforms. <i>Journal of Clinical Psychopharmacology</i> , 1998 , 18, 256	1.7	29
391	Appetite suppressant drugs as inhibitors of human cytochromes P450: in vitro inhibition of P450-2D6 by D- and L-fenfluramine, but not phentermine. <i>Journal of Clinical Psychopharmacology</i> , 1998 , 18, 338-41	1.7	12

390	Biochemical basis for deficient paracetamol glucuronidation in cats: an interspecies comparison of enzyme constraint in liver microsomes. <i>Journal of Pharmacy and Pharmacology</i> , 1997 , 49, 446-9	4.8	39
389	Differential effect of central versus parenteral administration of morphine sulfate on regional concentrations of reduced glutathione in rat brain. <i>Pharmacology</i> , 1997 , 54, 92-7	2.3	20
388	Influence of oral contraceptive use and cigarette smoking, alone and together, on antipyrine pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , 1997 , 37, 437-41	2.9	8
387	The NMDA receptor competitive antagonist CPP modulates benzodiazepine tolerance and discontinuation. <i>Pharmacology</i> , 1997 , 55, 217-27	2.3	27
386	Alterations in pharmacodynamics of anxiolytics in abstinent alcoholic men: subjective responses, abuse liability, and electroencephalographic effects of alprazolam, diazepam, and buspirone. <i>Journal of Clinical Pharmacology</i> , 1997 , 37, 64-73	2.9	17
385	Biotransformation of mestranol to ethinyl estradiol in vitro: the role of cytochrome P-450 2C9 and metabolic inhibitors. <i>Journal of Clinical Pharmacology</i> , 1997 , 37, 193-200	2.9	32
384	Molecular basis for deficient acetaminophen glucuronidation in cats. An interspecies comparison of enzyme kinetics in liver microsomes. <i>Biochemical Pharmacology</i> , 1997 , 53, 1041-7	6	136
383	Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. <i>Journal of Clinical Pharmacology</i> , 1997 , 37, 693-703	2.9	228
382	Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms. <i>Biological Psychiatry</i> , 1997 , 41, 377-80	7.9	24
381	Human cytochromes mediating N-demethylation of fluoxetine in vitro. <i>Psychopharmacology</i> , 1997 , 132, 402-7	4.7	60
380	Chronic alcohol abuse and the acute sedative and neurophysiologic effects of midazolam. <i>Psychopharmacology</i> , 1997 , 133, 293-9	4.7	14
379	Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. <i>British Journal of Clinical Pharmacology</i> , 1997 , 44, 495-8	3.8	70
378	Alprazolam hydroxylation by mouse liver microsomes in vitro: the effect of age and phenobarbital induction. <i>Biopharmaceutics and Drug Disposition</i> , 1997 , 18, 139-49	1.7	6
377	Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. <i>Biopharmaceutics and Drug Disposition</i> , 1997 , 18, 213-26	1.7	89
376	Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1. <i>Biopharmaceutics and Drug Disposition</i> , 1997 , 18, 227-40	1.7	62
375	Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. <i>Journal of Clinical Psychopharmacology</i> , 1997 , 17, 284-91	1.7	92
374	Can you provide a table of equivalences for benzodiazepines and other marketed benzodiazepine receptor agonists?. <i>Journal of Clinical Psychopharmacology</i> , 1997 , 17, 331	1.7	8
373	Hypnotic effects of low doses of quazepam in older insomniacs. <i>Journal of Clinical Psychopharmacology</i> , 1997 , 17, 401-6	1.7	19

372	Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies. <i>Journal of Clinical Pharmacology</i> , 1996 , 36, 792-8	2.9	45
371	Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. <i>Clinical Pharmacokinetics</i> , 1996 , 30, 52-76	6.2	61
370	Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. <i>Journal of Clinical Pharmacology</i> , 1996 , 36, 783-91	2.9	166
369	Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. <i>Psychopharmacology</i> , 1996 , 128, 398-407	4.7	90
368	Effect of diazepam on plasma gamma-aminobutyric acid in sons of alcoholic fathers. <i>Alcoholism: Clinical and Experimental Research</i> , 1996 , 20, 343-7	3.7	9
367	Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation. <i>British Journal of Clinical Pharmacology</i> , 1996 , 41, 339-43	3.8	39
366	Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: application to amitriptyline N-demethylation. <i>British Journal of Clinical Pharmacology</i> , 1996 , 41, 593-604	3.8	29
365	Influence of polyethylene glycol and acetone on the in vitro biotransformation of tamoxifen and alprazolam by human liver microsomes. <i>Journal of Pharmaceutical Sciences</i> , 1996 , 85, 1180-5	3.9	15
364	Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies. <i>Pharmacology</i> , 1996 , 52, 125-34	2.3	39
363	Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. <i>Journal of Clinical Psychopharmacology</i> , 1996 , 16, 104-12	1.7	63
362	Treatment, discontinuation, and psychomotor effects of diazepam in women with generalized anxiety disorder. <i>Journal of Clinical Psychopharmacology</i> , 1996 , 16, 202-7	1.7	9
361	Benzodiazepine sensitivity in panic disorder: effects of chronic alprazolam treatment. <i>Neuropsychopharmacology</i> , 1995 , 12, 147-57	8.7	27
360	Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology. <i>Clinical Pharmacokinetics</i> , 1995 , 29 Suppl 1, 33-43; discussion 43-4	6.2	89
359	Effects of diphenhydramine on human eye movements. <i>Psychopharmacology</i> , 1995 , 118, 280-6	4.7	12
358	Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. <i>Journal of Clinical Psychopharmacology</i> , 1995 , 15, 125-31	1.7	140
357	In memoriam the life of Milton Greenblatt. <i>Journal of Clinical Psychopharmacology</i> , 1995 , 15, 155-9	1.7	1
356	Eye movement effects of diazepam in sons of alcoholic fathers and male control subjects. <i>Alcoholism: Clinical and Experimental Research</i> , 1994 , 18, 324-32	3.7	35
355	Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies. <i>Clinical Pharmacology and Therapeutics</i> , 1994 , 56, 100-111	6.1	54

354	In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. <i>Journal of Clinical Pharmacology</i> , 1994 , 34, 1222-7	2.9	86
353	Clinical pharmacokinetics of antidepressants in the elderly. Therapeutic implications. <i>Clinical Pharmacokinetics</i> , 1993 , 24, 141-60	6.2	35
352	Clinical pharmacokinetics of alprazolam. Therapeutic implications. <i>Clinical Pharmacokinetics</i> , 1993 , 24, 453-71	6.2	201
351	Personality and benzodiazepine sensitivity in anxious patients and control subjects. <i>Psychiatry Research</i> , 1993 , 47, 151-62	9.9	36
350	Presystemic extraction: mechanisms and consequences. <i>Journal of Clinical Pharmacology</i> , 1993 , 33, 650-6.9		12
349	Use of benzodiazepines in anxiety disorders. <i>New England Journal of Medicine</i> , 1993 , 328, 1398-405	59.2	255
348	Chronic benzodiazepine administration. XI. Concurrent administration of PK11195 attenuates lorazepam discontinuation effects. <i>Neuropsychopharmacology</i> , 1993 , 8, 267-73	8.7	15
347	Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. <i>Pharmacology</i> , 1993 , 47, 268-76	2.3	84
346	Plasma alprazolam concentrations. Relation to efficacy and side effects in the treatment of panic disorder. <i>Archives of General Psychiatry</i> , 1993 , 50, 715-22		29
345	Norcocaine and N-hydroxynorcocaine formation in human liver microsomes: role of cytochrome P-450 3A4. <i>Pharmacology</i> , 1993 , 46, 294-300	2.3	51
344	Kinetic-Dynamic Modeling in Clinical. <i>Journal of Clinical Psychopharmacology</i> , 1993 , 13, 231-234	1.7	10
343	Antipyrine kinetics in patients with primary biliary cirrhosis. <i>Journal of Clinical Pharmacology</i> , 1993 , 33, 75-7	2.9	6
342	Inhibition of acetaminophen and lorazepam glucuronidation in vitro by probenecid. <i>Biopharmaceutics and Drug Disposition</i> , 1993 , 14, 119-30	1.7	24
341	Cognitive effects of beta-adrenergic antagonists after single doses: pharmacokinetics and pharmacodynamics of propranolol, atenolol, lorazepam, and placebo. <i>Clinical Pharmacology and Therapeutics</i> , 1993 , 53, 577-84	6.1	30
340	Benzodiazepine pharmacodynamics: utility of eye movement measures. <i>Psychopharmacology</i> , 1993 , 110, 85-91	4.7	38
339	Chronic benzodiazepine administration. XII. Anticonvulsant cross-tolerance but distinct neurochemical effects of alprazolam and lorazepam. <i>Psychopharmacology</i> , 1993 , 111, 91-5	4.7	14
338	Response to diazepam in sons of alcoholics. <i>Alcoholism: Clinical and Experimental Research</i> , 1992 , 16, 1057-63	3.7	28
337	Pharmacokinetic principles in clinical medicine. <i>Journal of Clinical Pharmacology</i> , 1992 , 32, 118-23	2.9	2

336	Benzodiazepine receptor binding of nonbenzodiazepines in vivo: alpidem, zolpidem and zopiclone. <i>Brain Research Bulletin</i> , 1992 , 29, 905-8	3.9	35
335	Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. <i>Clinical Pharmacology and Therapeutics</i> , 1992 , 52, 139-50	6.1	72
334	Fluoxetine impairs clearance of alprazolam but not of clonazepam. <i>Clinical Pharmacology and Therapeutics</i> , 1992 , 52, 479-86	6.1	121
333	Benzodiazepine receptor binding of benzodiazepine hypnotics: receptor and ligand specificity. <i>Pharmacology Biochemistry and Behavior</i> , 1992 , 43, 413-6	3.9	18
332	Effect of acute and chronic benzodiazepines on plasma GABA in anxious patients and controls. <i>Psychopharmacology</i> , 1992 , 109, 153-6	4.7	17
331	Contribution of the gastrointestinal tract to lorazepam conjugation and clonazepam nitroreduction. <i>Pharmacology</i> , 1991 , 42, 36-48	2.3	3
330	Appropriate use and regulatory control of benzodiazepines. <i>Journal of Clinical Pharmacology</i> , 1991 , 31, 781-4	2.9	31
329	Differential side effect profile of triazolam versus flurazepam in elderly patients undergoing rehabilitation therapy. <i>Journal of Clinical Pharmacology</i> , 1991 , 31, 168-73	2.9	9
328	Validity of self-reports of caffeine use. <i>Journal of Clinical Pharmacology</i> , 1991 , 31, 677-80	2.9	15
327	Prenatal benzodiazepine administration. II. Lorazepam exposure is associated with decreases in [35S]TBPS binding but not benzodiazepine binding. <i>Pharmacology Biochemistry and Behavior</i> , 1991 , 40, 429-32	3.9	6
326	Modification of gamma-aminobutyric acidA receptor binding and function by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vitro and in vivo: effects of aging. <i>Journal of Neurochemistry</i> , 1991 , 56, 1241-7	6	19
325	Pharmacokinetic and dynamic correlates of intravenous alprazolam challenge. <i>Clinical Pharmacology and Therapeutics</i> , 1991 , 50, 656-62	6.1	2
324	Chronic benzodiazepine administration. VII. Behavioral tolerance and withdrawal and receptor alterations associated with clonazepam administration. <i>Psychopharmacology</i> , 1991 , 104, 225-30	4.7	30
323	Comparative pharmacokinetics of alprazolam and lorazepam in humans and in African Green Monkeys. <i>Psychopharmacology</i> , 1991 , 104, 103-5	4.7	17
322	Sensitivity to triazolam in the elderly. <i>New England Journal of Medicine</i> , 1991 , 324, 1691-8	59.2	234
321	Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part I). <i>Clinical Pharmacokinetics</i> , 1991 , 21, 165-77	6.2	140
320	Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part II). <i>Clinical Pharmacokinetics</i> , 1991 , 21, 262-73	6.2	70
319	Accelerated benzodiazepine receptor recovery after lorazepam discontinuation. <i>FASEB Journal</i> , 1991 , 5, 93-7	0.9	4

3 ¹⁸	Benzodiazepine receptor binding response to acute and chronic stress is increased in aging animals. <i>Pharmacology</i> , 1991 , 42, 181-7	2.3	7
3 ¹⁷	Differential effect of cigarette smoking on antipyrine oxidation versus acetaminophen conjugation. <i>Pharmacology</i> , 1990 , 40, 77-84	2.3	13
3 ¹⁶	Validity of a two-point acetaminophen pharmacokinetic study. <i>Therapeutic Drug Monitoring</i> , 1990 , 12, 35-9	3.2	4
3 ¹⁵	The neuropsychiatric effects of aspartame in normal volunteers. <i>Journal of Clinical Pharmacology</i> , 1990 , 30, 454-60	2.9	22
3 ¹⁴	New pharmacokinetic methods. III. Two simple test for "deep pool effect". <i>Journal of Clinical Pharmacology</i> , 1990 , 30, 680-5	2.9	8
3 ¹³	Gas chromatographic analysis of alprazolam in plasma: replicability, stability and specificity. <i>Biomedical Applications</i> , 1990 , 534, 202-7		18
3 ¹²	Benzodiazepine concentrations in brain directly reflect receptor occupancy: studies of diazepam, lorazepam, and oxazepam. <i>Psychopharmacology</i> , 1990 , 102, 373-8	4.7	58
3 ¹¹	Separate and combined effects of caffeine and alprazolam on motor activity and benzodiazepine receptor binding in vivo. <i>Psychopharmacology</i> , 1990 , 101, 539-44	4.7	12
3 ¹⁰	Chronic morphine administration augments benzodiazepine binding and GABA _A receptor function. <i>Psychopharmacology</i> , 1990 , 101, 545-9	4.7	29
3 ⁰⁹	Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. <i>Biopharmaceutics and Drug Disposition</i> , 1990 , 11, 185-9	1.7	19
3 ⁰⁸	Oxidative versus conjugative biotransformation of temazepam. <i>Biopharmaceutics and Drug Disposition</i> , 1990 , 11, 499-506	1.7	27
3 ⁰⁷	Reduced systemic absorption of intrabronchial lidocaine by high-frequency nebulization. <i>Journal of Clinical Pharmacology</i> , 1990 , 30, 795-7	2.9	5
3 ⁰⁶	New pharmacokinetic methods: I. Estimation of mean serum concentration from trough serum concentration. <i>Journal of Clinical Pharmacology</i> , 1990 , 30, 482-8	2.9	2
3 ⁰⁵	Influence of vitamin E supplementation on antipyrine clearance in the cebus monkey. <i>Nutrition Research</i> , 1990 , 10, 1045-1051	4	3
3 ⁰⁴	Augmentation of GABA _A receptor function by chronic exposure to GABA-neutral and GABA-negative benzodiazepine ligands in cultured cortical neurons. <i>Biochemical Pharmacology</i> , 1990 , 40, 1337-44	6	12
3 ⁰³	Differential effects of chronic lorazepam and alprazolam on benzodiazepine binding and GABA _A -receptor function. <i>British Journal of Pharmacology</i> , 1990 , 101, 839-42	8.6	23
3 ⁰²	Caffeine-induced behavioural stimulation is dose- and concentration-dependent. <i>British Journal of Pharmacology</i> , 1990 , 100, 435-40	8.6	21
3 ⁰¹	Doxylamine and diphenhydramine pharmacokinetics in women on low-dose estrogen oral contraceptives. <i>Journal of Clinical Pharmacology</i> , 1989 , 29, 257-60	2.9	17

300	Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics. Flurazepam, temazepam, and triazolam. <i>Archives of General Psychiatry</i> , 1989 , 46, 326-32		77
299	Interaction of caffeine with the GABAA receptor complex: alterations in receptor function but not ligand binding. <i>European Journal of Pharmacology</i> , 1989 , 172, 453-9		41
298	Bioequivalence of a generic brand of diazepam. <i>Biopharmaceutics and Drug Disposition</i> , 1989 , 10, 597-605		11
297	Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. <i>Clinical Pharmacology and Therapeutics</i> , 1989 , 45, 356-65	6.1	147
296	Therapeutic serum lidocaine and metabolite concentrations in patients undergoing electrophysiologic study after discontinuation of intravenous lidocaine infusion. <i>American Heart Journal</i> , 1989 , 117, 1060-4	4.9	16
295	Chronic benzodiazepine administration. IV. Rapid development of tolerance and receptor downregulation associated with alprazolam administration. <i>Biochemical Pharmacology</i> , 1989 , 38, 3773-7 ⁶		52
294	Lorazepam discontinuation promotes inverse agonist effects of benzodiazepines. <i>British Journal of Pharmacology</i> , 1989 , 98, 451-4	8.6	19
293	Lack of effect of influenza vaccine on the pharmacokinetics of antipyrine, alprazolam, paracetamol (acetaminophen) and lorazepam. <i>Clinical Pharmacokinetics</i> , 1989 , 16, 180-5	6.2	11
292	Clearance of the antihistamine doxylamine. Reduced in elderly men but not in elderly women. <i>Clinical Pharmacokinetics</i> , 1989 , 16, 312-6	6.2	23
291	Arithmetic versus harmonic mean values of elimination half-life: a study of triazolam. <i>Journal of Clinical Pharmacology</i> , 1989 , 29, 655-6	2.9	4
290	Implications of altered drug disposition in the elderly: studies of benzodiazepines. <i>Journal of Clinical Pharmacology</i> , 1989 , 29, 866-72	2.9	83
289	Chronic treatment with fluvoxamine, clovoxamine, and placebo: interaction with digoxin and effects on sleep and alertness. <i>Journal of Clinical Pharmacology</i> , 1989 , 29, 91-5	2.9	21
288	A large-sample study of diazepam pharmacokinetics. <i>Therapeutic Drug Monitoring</i> , 1989 , 11, 652-7	3.2	41
287	Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition. <i>Pharmacology</i> , 1989 , 38, 327-34	2.3	27
286	HPLC Determination of Beta-Adrenergic Blockers in Biological Fluids. <i>Techniques and Instrumentation in Analytical Chemistry</i> , 1989 , 4, 159-187		
285	Kinetics, brain uptake, and receptor binding characteristics of flurazepam and its metabolites. <i>Psychopharmacology</i> , 1988 , 94, 386-91	4.7	24
284	Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo. <i>Clinical Pharmacology and Therapeutics</i> , 1988 , 44, 326-34	6.1	69
283	Lorazepam conjugation is unimpaired in burn trauma. <i>Clinical Pharmacology and Therapeutics</i> , 1988 , 43, 250-5	6.1	26

282	Differential modulation of benzodiazepine receptor binding by ethanol in LS and SS mice. <i>Pharmacology Biochemistry and Behavior</i> , 1988 , 29, 471-7	3.9	17
281	Low-dose alprazolam augments motor activity in mice. <i>Pharmacology Biochemistry and Behavior</i> , 1988 , 30, 511-3	3.9	23
280	Modulation of benzodiazepine receptor binding in mouse brain by adrenalectomy and steroid replacement. <i>Brain Research</i> , 1988 , 446, 314-20	3.7	44
279	Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam. <i>Journal of Clinical Pharmacology</i> , 1988 , 28, 853-9	2.9	31
278	Suppression of norepinephrine appearance rate in plasma by diazepam in humans. <i>Life Sciences</i> , 1988 , 43, 1615-23	6.8	21
277	Benzodiazepine binding sites on PC12 cells: modulation by nerve growth factor and forskolin. <i>Neuroscience Letters</i> , 1988 , 89, 342-8	3.3	5
276	Antipyrine absorption and disposition in the elderly. <i>Pharmacology</i> , 1988 , 36, 125-33	2.3	26
275	Antipyrine pharmacokinetics in women receiving conjugated estrogens. <i>Journal of Clinical Pharmacology</i> , 1988 , 28, 463-6	2.9	7
274	Alprazolam pharmacokinetics in women on low-dose oral contraceptives. <i>Journal of Clinical Pharmacology</i> , 1988 , 28, 454-7	2.9	22
273	Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam. <i>Journal of Clinical Pharmacology</i> , 1988 , 28, 240-5	2.9	24
272	Pharmacodynamic comparison of L-bunolol with propranolol, metoprolol, and placebo. <i>Journal of Clinical Pharmacology</i> , 1988 , 28, 1101-5	2.9	
271	Triazolam kinetics: interaction with cimetidine, propranolol, and the combination. <i>Journal of Clinical Pharmacology</i> , 1988 , 28, 228-33	2.9	17
270	Pharmacokinetics and CSF entry of flurazepam in dogs. <i>Pharmacology</i> , 1988 , 36, 166-71	2.3	4
269	High-affinity benzodiazepine binding sites on rat peritoneal mast cells and RBL-1 cells: binding characteristics and effects on granule secretion. <i>Pharmacology</i> , 1988 , 36, 52-60	2.3	13
268	Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam. <i>New England Journal of Medicine</i> , 1987 , 317, 722-8	59.2	83
267	Measurement of clonazepam by electron-capture gas-liquid chromatography with application to single-dose pharmacokinetics. <i>Journal of Analytical Toxicology</i> , 1987 , 11, 55-7	2.9	13
266	Estimation of the elimination half-life of a drug at any serum concentration when the Km and Vmax of the drug are known: calculations and validation with phenytoin. <i>Journal of Clinical Pharmacology</i> , 1987 , 27, 318-20	2.9	4
265	Antipyrine and lidocaine are cleared faster in horses than in humans: acetaminophen may be handled similarly. <i>Pharmacology</i> , 1987 , 34, 192-200	2.3	7

264	Drug absorption rate: a critical component of bioequivalence assessment in psychopharmacology. <i>Journal of Clinical Pharmacology</i> , 1987 , 27, 85-6	2.9	5
263	Glycoconjugates as noninvasive probes of intrahepatic metabolism: I. Kinetics of label incorporation with evidence of a common precursor UDP-glucose pool for secreted glycoconjugates. <i>Metabolism: Clinical and Experimental</i> , 1987 , 36, 988-94	12.7	24
262	Rapid increase in brain benzodiazepine receptor binding following defeat stress in mice. <i>Brain Research</i> , 1987 , 414, 395-400	3.7	108
261	Pharmacokinetics of intravenous caffeine: comparison of high-performance liquid chromatographic and gas chromatographic methods. <i>Biomedical Applications</i> , 1987 , 422, 274-80		17
260	Poor bioavailability of CGS 8216 in a water/tween vehicle following intraperitoneal injection. <i>Psychopharmacology</i> , 1987 , 91, 260-1	4.7	7
259	A simplex procedure for fitting nonlinear pharmacokinetic models. <i>Computers in Biology and Medicine</i> , 1987 , 17, 199-208	7	28
258	Benzodiazepine receptor binding: influence of physiologic and pharmacologic factors. <i>Biopharmaceutics and Drug Disposition</i> , 1987 , 8, 103-14	1.7	23
257	Gas chromatographic analysis of underivatized tocinide. <i>Biomedical Applications</i> , 1987 , 419, 339-44		
256	Tyr-MIF-1 augments benzodiazepine receptor binding in vivo. <i>Pharmacology Biochemistry and Behavior</i> , 1987 , 28, 521-4	3.9	18
255	Trazodone kinetics: effect of age, gender, and obesity. <i>Clinical Pharmacology and Therapeutics</i> , 1987 , 42, 193-200	6.1	102
254	Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. <i>Clinical Pharmacology and Therapeutics</i> , 1987 , 41, 562-70	6.1	43
253	The interactions of propranolol and ketanserin. <i>Clinical Pharmacology and Therapeutics</i> , 1987 , 41, 55-60	6.1	5
252	Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam. <i>Journal of Neurochemistry</i> , 1987 , 49, 1595-601	6	28
251	Pharmacokinetic aspects of drug therapy in the elderly. <i>Therapeutic Drug Monitoring</i> , 1986 , 8, 249-55	3.2	49
250	Interaction of diazepam with famotidine and cimetidine, two H ₂ -receptor antagonists. <i>Journal of Clinical Pharmacology</i> , 1986 , 26, 299-303	2.9	26
249	Cyclosporine blood concentrations determined by specific versus nonspecific assay methods. <i>Journal of Clinical Pharmacology</i> , 1986 , 26, 367-71	2.9	8
248	Distribution. <i>Journal of Clinical Pharmacology</i> , 1986 , 26, 425-6	2.9	2
247	Pharmacokinetics: dose-dependent changes. <i>Journal of Clinical Pharmacology</i> , 1986 , 26, 463-8	2.9	8

246	Pharmacokinetics and clinical effects of alprazolam following single and multiple oral doses in patients with panic disorder. <i>Journal of Clinical Pharmacology</i> , 1986 , 26, 292-8	2.9	37
245	Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin. <i>Arthritis and Rheumatism</i> , 1986 , 29, 971-80		39
244	Determination of ciramadol and dezocine, two new analgesics, by high-performance liquid chromatography using electrochemical detection. <i>Biomedical Applications</i> , 1986 , 374, 215-20		9
243	Determination of zopiclone in plasma by liquid chromatography with application to steady-state monitoring. <i>Biomedical Applications</i> , 1986 , 380, 211-5		20
242	Sedative effects and impaired learning and recall after single oral doses of lorazepam. <i>Clinical Pharmacology and Therapeutics</i> , 1986 , 39, 526-9	6.1	48
241	Pharmacokinetics of oxaprozin and other nonsteroidal antiinflammatory agents. <i>Seminars in Arthritis and Rheumatism</i> , 1986 , 15, 18-26	5.3	8
240	Enhanced bioavailability of triazolam following sublingual versus oral administration. <i>Journal of Clinical Pharmacology</i> , 1986 , 26, 208-10	2.9	38
239	More than skin deep: transdermal drug-delivery systems. <i>New England Journal of Medicine</i> , 1986 , 314, 1638-9	59.2	16
238	Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration. <i>Journal of Clinical Pharmacology</i> , 1986 , 26, 529-33	2.9	77
237	Drug disposition in obese humans. An update. <i>Clinical Pharmacokinetics</i> , 1986 , 11, 199-213	6.2	147
236	Large theophylline requirements due to high theophylline clearance: verification by the antipyrine test. <i>Pharmacology</i> , 1986 , 32, 226-31	2.3	10
235	Cerebrospinal fluid uptake and peripheral distribution of centrally acting drugs: relation to lipid solubility. <i>Journal of Pharmacy and Pharmacology</i> , 1985 , 37, 428-31	4.8	25
234	Kinetics of diazepam, midazolam, and lorazepam in cigarette smokers. <i>Chest</i> , 1985 , 87, 223-6	5.3	42
233	Staggered stable isotope administration technique for study of drug distribution. <i>Journal of Clinical Pharmacology</i> , 1985 , 25, 309-12	2.9	5
232	Studies with stable isotopes III: Pharmacokinetics of tracer doses of drug. <i>Journal of Clinical Pharmacology</i> , 1985 , 25, 59-63	2.9	15
231	Effect of ketanserin on the kinetics of digoxin and digitoxin. <i>Journal of Cardiovascular Pharmacology</i> , 1985 , 7, 205-7	3.1	7
230	Studies with stable isotopes I: Changes in phenytoin pharmacokinetics and biotransformation during monotherapy. <i>Journal of Clinical Pharmacology</i> , 1985 , 25, 43-50	2.9	18
229	Phenelzine and the dream machine--ramblings and reflections. <i>Journal of Clinical Psychopharmacology</i> , 1985 , 5, 65	1.7	55

228	The admissibility of positive EMIT results as scientific evidence: counting facts, not heads. <i>Journal of Clinical Psychopharmacology</i> , 1985 , 5, 114-6	1.7	4
227	Effect of alprazolam on digoxin kinetics and creatinine clearance. <i>Clinical Pharmacology and Therapeutics</i> , 1985 , 38, 595-8	6.1	12
226	Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. <i>Clinical Pharmacology and Therapeutics</i> , 1985 , 38, 648-51	6.1	31
225	Age, sex, and nitrazepam kinetics: relation to antipyrine disposition. <i>Clinical Pharmacology and Therapeutics</i> , 1985 , 38, 697-703	6.1	35
224	Triazolam and ethanol interaction: kinetic and dynamic consequences. <i>Clinical Pharmacology and Therapeutics</i> , 1985 , 37, 558-62	6.1	28
223	Simplified gas chromatographic assay of underivatized nitrazepam in plasma. <i>Biomedical Applications</i> , 1985 , 337, 131-5		7
222	Ibuprofen disposition in obese individuals. <i>Arthritis and Rheumatism</i> , 1985 , 28, 1117-21		38
221	Ibuprofen kinetics in patients with renal insufficiency who are receiving maintenance hemodialysis. <i>Arthritis and Rheumatism</i> , 1985 , 28, 1430-4		8
220	Pharmacokinetics and bioavailability of ciramadol, a new analgesic. <i>Drug Development Research</i> , 1985 , 6, 61-66	5.1	
219	Comment: Triazolam-cimetidine reaction. <i>Drug Intelligence & Clinical Pharmacy</i> , 1985 , 19, 679		
218	Tissue distribution of diazepam and its metabolite desmethyldiazepam: a human autopsy study. <i>Journal of Clinical Pharmacology</i> , 1985 , 25, 613-5	2.9	16
217	Studies with stable isotopes II: Phenobarbital pharmacokinetics during monotherapy. <i>Journal of Clinical Pharmacology</i> , 1985 , 25, 51-8	2.9	27
216	Pharmacologic properties of acebutolol: relationship of hydrophilicity to central nervous system penetration. <i>American Heart Journal</i> , 1985 , 109, 1120-5	4.9	8
215	Liquid chromatographic retention of beta-adrenoceptor antagonists: an index of lipid solubility. <i>Journal of Pharmacy and Pharmacology</i> , 1984 , 36, 400-1	4.8	12
214	Quantitation by gas chromatography of the 1- and 4-hydroxy metabolites of midazolam in human plasma. <i>Pharmacology</i> , 1984 , 29, 158-64	2.3	49
213	Pharmacokinetics, central nervous system uptake, and lipid solubility of propranolol, acebutolol, and sotalol. <i>Cardiology</i> , 1984 , 71, 307-14	1.6	28
212	Plasma levels of trazodone: methodology and applications. <i>Pharmacology</i> , 1984 , 28, 42-6	2.3	18
211	Comparative single-dose kinetics of oxazolam, prazepam, and clorazepate: three precursors of desmethyldiazepam. <i>Journal of Clinical Pharmacology</i> , 1984 , 24, 446-51	2.9	12

210	Benzodiazepine drug-drug interactions commonly occurring in clinical practice. <i>Current Medical Research and Opinion</i> , 1984 , 8 Suppl 4, 80-93	2.5	17
209	Clinical importance of the interaction of diazepam and cimetidine. <i>New England Journal of Medicine</i> , 1984 , 310, 1639-43	59.2	93
208	Rapid high-performance liquid chromatographic analysis of oxaprozin, a non-steroidal anti-inflammatory agent. <i>Biomedical Applications</i> , 1984 , 310, 445-9		9
207	Imipramine disposition in users of oral contraceptive steroids. <i>Clinical Pharmacology and Therapeutics</i> , 1984 , 35, 792-7	6.1	56
206	Propranolol interactions with diazepam, lorazepam, and alprazolam. <i>Clinical Pharmacology and Therapeutics</i> , 1984 , 36, 451-5	6.1	28
205	Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam. <i>Clinical Pharmacology and Therapeutics</i> , 1984 , 35, 188-92	6.1	31
204	Trimipramine kinetics and absolute bioavailability: use of gas-liquid chromatography with nitrogen-phosphorus detection. <i>Clinical Pharmacology and Therapeutics</i> , 1984 , 35, 348-53	6.1	34
203	Plasma protein binding of drugs after severe burn injury. <i>Clinical Pharmacology and Therapeutics</i> , 1984 , 35, 535-9	6.1	75
202	Simultaneous determination of lidocaine and its deethylated metabolites using gas-liquid chromatography with nitrogen-phosphorus detection. <i>Biomedical Applications</i> , 1984 , 307, 200-205		14
201	Absorption and disposition of ibuprofen in the elderly. <i>Arthritis and Rheumatism</i> , 1984 , 27, 1066-9		61
200	Noninteraction of temazepam and cimetidine. <i>Journal of Pharmaceutical Sciences</i> , 1984 , 73, 399-401	3.9	14
199	Haloperidol determination in serum and cerebrospinal fluid using gas-liquid chromatography with nitrogen-phosphorus detection: Application to pharmacokinetic studies. <i>Biomedical Applications</i> , 1984 , 307, 194-199		16
198	A pharmacokinetic study of CGS-8216, a benzodiazepine receptor ligand, in the rat. <i>Psychopharmacology</i> , 1984 , 84, 420-2	4.7	15
197	Absolute bioavailability of imipramine: influence of food. <i>Psychopharmacology</i> , 1984 , 83, 104-6	4.7	20
196	The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. <i>Clinical Pharmacokinetics</i> , 1984 , 9, 177-83	6.2	67
195	Effect of cimetidine on digoxin kinetics and creatinine clearance. <i>American Heart Journal</i> , 1984 , 107, 170-29	4.9	16
194	Lidocaine disposition in obesity. <i>American Journal of Cardiology</i> , 1984 , 53, 1183-6	3	61
193	Pharmacokinetic studies on Ro 15-1788, a benzodiazepine receptor ligand, in the brain of the rat. <i>Brain Research</i> , 1984 , 290, 183-6	3.7	89

192	Interaction of cimetidine with oxazepam, lorazepam, and flurazepam. <i>Journal of Clinical Pharmacology</i> , 1984 , 24, 187-93	2.9	18
191	Some biochemical correlates of panic attacks with agoraphobia and their response to a new treatment. <i>Journal of Clinical Psychopharmacology</i> , 1984 , 4, 66-75	1.7	110
190	Is temazepam an accumulating hypnotic?. <i>Journal of Clinical Pharmacology</i> , 1984 , 24, 58-64	2.9	12
189	Evaluation of the hypothalamic-pituitary effects of digoxin. <i>Journal of Clinical Pharmacology</i> , 1984 , 24, 474-9	2.9	5
188	Absolute bioavailability and effect of food and antacid on diazepam absorption from a slow-release preparation. <i>Journal of Clinical Pharmacology</i> , 1984 , 24, 255-63	2.9	15
187	Pharmacokinetic noninteraction of triazolam and ethanol. <i>Journal of Clinical Psychopharmacology</i> , 1984 , 4, 106-7	1.7	17
186	Differential effects of isoniazid and oral contraceptive steroids on antipyrine oxidation and acetaminophen conjugation. <i>Pharmacology</i> , 1984 , 28, 188-95	2.3	15
185	Effect of Age, Gender, and Obesity on Midazolam Kinetics. <i>Anesthesiology</i> , 1984 , 61, 27-35	4.3	469
184	Concentration-independent plasma protein binding of benzodiazepines. <i>Journal of Pharmacy and Pharmacology</i> , 1983 , 35, 179-80	4.8	97
183	Improved liquid chromatographic analysis of phenytoin and salicylate using radial compression separation. <i>Biomedical Applications</i> , 1983 , 275, 450-7		16
182	Methods for the determination of lorazepam and chlordiazepoxide and metabolites in brain tissue. A comparison with plasma concentrations in the rat. <i>Biomedical Applications</i> , 1983 , 277, 201-8		24
181	Halazepam as a precursor of desmethyldiazepam: quantitation by electron-capture gas-liquid chromatography. <i>Psychopharmacology</i> , 1983 , 80, 178-80	4.7	9
180	Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. <i>Psychopharmacology</i> , 1983 , 80, 275-8	4.7	64
179	Diphenhydramine determination in human plasma by gas-liquid chromatography using nitrogen-phosphorus detection: application to single low-dose pharmacokinetic studies. <i>Journal of Pharmaceutical Sciences</i> , 1983 , 72, 941-3	3.9	21
178	Absolute and relative bioavailability of oral acetaminophen preparations. <i>Journal of Pharmaceutical Sciences</i> , 1983 , 72, 955-8	3.9	60
177	Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics. <i>Drug Metabolism Reviews</i> , 1983 , 14, 251-92	7	93
176	Reduced single-dose clearance of clobazam in elderly men predicts increased multiple-dose accumulation. <i>Clinical Pharmacokinetics</i> , 1983 , 8, 83-94	6.2	30
175	Clinical pharmacokinetics of the newer benzodiazepines. <i>Clinical Pharmacokinetics</i> , 1983 , 8, 233-52	6.2	101

174	The behavioural effects of lorazepam are poorly related to its concentration in the brain. <i>Life Sciences</i> , 1983 , 32, 2033-40	6.8	21
173	Is volume of distribution at steady state a meaningful kinetic variable?. <i>Journal of Clinical Pharmacology</i> , 1983 , 23, 391-400	2.9	16
172	Drug toxicity in patients receiving digoxin and quinidine. <i>American Heart Journal</i> , 1983 , 105, 1025-8	4.9	15
171	Antipyretic analgesic drugs as models for studies of drug disposition in old age. <i>American Journal of Medicine</i> , 1983 , 75, 127-32	2.4	10
170	Alprazolam kinetics in the elderly. Relation to antipyrine disposition. <i>Archives of General Psychiatry</i> , 1983 , 40, 287-90		100
169	Metoprolol or propranolol does not alter the kinetics of procainamide. <i>Journal of Cardiovascular Pharmacology</i> , 1983 , 5, 392-5	3.1	5
168	Absolute Bioavailability of Oral and Intramuscular Diazepam. <i>Anesthesia and Analgesia</i> , 1983 , 62, 1777-8	3.9	72
167	Reduced distribution and clearance of acetaminophen in patients with congestive heart failure. <i>Journal of Cardiovascular Pharmacology</i> , 1983 , 5, 697-9	3.1	10
166	Drug therapy. Current status of benzodiazepines. <i>New England Journal of Medicine</i> , 1983 , 309, 410-6	59.2	215
165	Impairment of lidocaine clearance in elderly male subjects. <i>Journal of Cardiovascular Pharmacology</i> , 1983 , 5, 1093-6	3.1	74
164	Dose-independent pharmacokinetics of intravenous lidocaine in humans. <i>Journal of Clinical Pharmacology</i> , 1983 , 23, 186-8	2.9	9
163	Prolonged accumulation of diazepam in obesity. <i>Journal of Clinical Pharmacology</i> , 1983 , 23, 369-76	2.9	57
162	Ibuprofen does not impair antipyrine clearance. <i>Journal of Clinical Pharmacology</i> , 1983 , 23, 517-22	2.9	3
161	Cimetidine impairs nitrazepam clearance. <i>Clinical Pharmacology and Therapeutics</i> , 1983 , 34, 227-30	6.1	27
160	Pilot pharmacokinetic study of brotizolam, a thienodiazepine hypnotic, using electron-capture gas-liquid chromatography. <i>Sleep</i> , 1983 , 6, 72-6	1.1	12
159	Determination of Ro 15-1788, a benzodiazepine antagonist, in human plasma by gas-liquid chromatography with nitrogen-phosphorus detection. Application to single-dose pharmacokinetic studies. <i>Pharmacology</i> , 1983 , 26, 285-9	2.3	12
158	Repeated diazepam dosing in cirrhotic patients: cumulation and sedation. <i>Clinical Pharmacology and Therapeutics</i> , 1983 , 33, 471-6	6.1	49
157	Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. <i>Clinical Pharmacology and Therapeutics</i> , 1983 , 33, 628-32	6.1	47

156	Drug therapy: drug disposition in old age. <i>New England Journal of Medicine</i> , 1982 , 306, 1081-8	59.2	541
155	Kinetics of high-dose i.v. diazepam. <i>British Journal of Anaesthesia</i> , 1982 , 54, 849-52	5.4	12
154	Pharmacokinetic equivalence of stable-isotope-labeled and unlabeled drugs. Phenobarbital in man. <i>Journal of Clinical Pharmacology</i> , 1982 , 22, 309-15	2.9	24
153	Impairment of diazepam metabolism by low-dose estrogen-containing oral-contraceptive steroids. <i>New England Journal of Medicine</i> , 1982 , 306, 791-2	59.2	87
152	Importance of protein binding for the interpretation of serum or plasma drug concentrations. <i>Journal of Clinical Pharmacology</i> , 1982 , 22, 259-63	2.9	101
151	Physiologic changes in old age: relation to altered drug disposition. <i>Journal of the American Geriatrics Society</i> , 1982 , 30, 56-10	5.6	27
150	Age does not alter acetaminophen absorption. <i>Journal of the American Geriatrics Society</i> , 1982 , 30, 240-45.6	4.6	45
149	Clobazam kinetics: intrasubject variability and effect of food on adsorption. <i>Journal of Clinical Pharmacology</i> , 1982 , 22, 69-73	2.9	39
148	Cimetidine impairs clearance of antipyrine and desmethyldiazepam in the elderly. <i>Journal of the American Geriatrics Society</i> , 1982 , 30, 684-9	5.6	28
147	Daytime carryover of triazolam and flurazepam in elderly insomniacs. <i>Sleep</i> , 1982 , 5, 361-71	1.1	114
146	A clinical study of flurazepam. <i>Sleep</i> , 1982 , 5, 350-60	1.1	30
145	Effect of food on acetaminophen absorption in young and elderly subjects. <i>Journal of Clinical Pharmacology</i> , 1982 , 22, 571-6	2.9	47
144	Pharmacokinetics of drugs in obesity. <i>Clinical Pharmacokinetics</i> , 1982 , 7, 108-24	6.2	95
143	Disease-related alterations in cardiac glycoside disposition. <i>Clinical Pharmacokinetics</i> , 1982 , 7, 434-51	6.2	12
142	Liquid chromatographic determination of chlordiazepoxide and metabolites in plasma. <i>Pharmacology</i> , 1982 , 24, 261-6	2.3	12
141	Automated electron-capture gas chromatographic analysis of flunitrazepam in plasma. <i>Pharmacology</i> , 1982 , 24, 82-7	2.3	8
140	Diazepam absorption: effects of age, sex, and Billroth gastrectomy. <i>Digestive Diseases and Sciences</i> , 1982 , 27, 225-30	4	38
139	Kinetics and cardiac effects of propranolol in humans. <i>Klinische Wochenschrift</i> , 1982 , 60, 521-5		10

138	Desmethyldiazepam kinetics after intravenous, intramuscular, and oral administration of clorazepate dipotassium. <i>Klinische Wochenschrift</i> , 1982 , 60, 411-5		20
137	Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. <i>Journal of Pharmaceutical Sciences</i> , 1982 , 71, 248-52	3.9	93
136	Prolongation of drug half-life due to obesity: studies of desmethyldiazepam (clorazepate). <i>Journal of Pharmaceutical Sciences</i> , 1982 , 71, 942-4	3.9	38
135	Obesity, sex, and acetaminophen disposition. <i>Clinical Pharmacology and Therapeutics</i> , 1982 , 31, 783-90	6.1	99
134	Acetaminophen kinetics in the elderly. <i>Clinical Pharmacology and Therapeutics</i> , 1982 , 31, 151-6	6.1	78
133	Steady-state plasma desmethyldiazepam during long-term clorazepate use: effects of antacids. <i>Clinical Pharmacology and Therapeutics</i> , 1982 , 31, 180-3	6.1	8
132	Digoxin disposition in obesity: clinical pharmacokinetic investigation. <i>American Heart Journal</i> , 1981 , 102, 740-4	4.9	73
131	Effect of magnesium--aluminum hydroxide and kaolin--pectin on absorption of digoxin from tablets and capsules. <i>Journal of Clinical Pharmacology</i> , 1981 , 21, 26-30	2.9	14
130	Clinical pharmacokinetics of oxazepam and lorazepam. <i>Clinical Pharmacokinetics</i> , 1981 , 6, 89-105	6.2	227
129	Lorazepam: a review of its clinical pharmacological properties and therapeutic uses. <i>Drugs</i> , 1981 , 21, 162-200	12.1	59
128	Alcohol does not enhance diazepam absorption. <i>Pharmacology</i> , 1981 , 22, 263-8	2.3	21
127	Neuropsychiatric sequelae of pharmacotherapy of cardiac arrhythmias and hypertension. <i>Journal of Clinical Psychopharmacology</i> , 1981 , 1, 394-8	1.7	5
126	Kinetics of oxazepam and lorazepam in two subjects with Gilbert syndrome. <i>Journal of Clinical Psychopharmacology</i> , 1981 , 1, 400-2	1.7	8
125	Comparative protein binding of diazepam and desmethyldiazepam. <i>Journal of Clinical Pharmacology</i> , 1981 , 21, 219-23	2.9	17
124	Tricyclic antidepressant determination in human plasma by gas-liquid chromatography using nitrogen-phosphorous detection: application to single-dose pharmacokinetic studies. <i>Pharmacology</i> , 1981 , 23, 57-63	2.3	21
123	Impairment of digoxin clearance by coadministration of quinidine. <i>Journal of Clinical Pharmacology</i> , 1981 , 21, 396-400	2.9	22
122	The specificity of the extraction fluorescence assay for serum or plasma quinidine. <i>Journal of Clinical Pharmacology</i> , 1981 , 21, 333-6	2.9	
121	Kinetic equivalence of stable-isotope-labeled and unlabeled phenytoin. <i>Clinical Pharmacology and Therapeutics</i> , 1981 , 29, 511-5	6.1	29

120	Effects of desmethyldiazepam on diazepam kinetics: a study of effects of a metabolite on parent drug disposition. <i>Clinical Pharmacology and Therapeutics</i> , 1981 , 29, 757-61	6.1	12
119	Impairment of antipyrine metabolism by low-dose oral contraceptive steroids. <i>Clinical Pharmacology and Therapeutics</i> , 1981 , 29, 106-10	6.1	50
118	Effect of age and gender on disposition of temazepam. <i>Journal of Pharmaceutical Sciences</i> , 1981 , 70, 1104-7	3.9	130
117	Benzodiazepine overdosage: plasma concentrations and clinical outcome. <i>Psychopharmacology</i> , 1981 , 73, 381-3	4.7	29
116	Effect of age and sex on disposition of desmethyldiazepam formed from its precursor clorazepate. <i>Psychopharmacology</i> , 1981 , 75, 193-7	4.7	57
115	Binding of diazepam and desmethyldiazepam to plasma protein: concentration-dependence and interactions. <i>Psychopharmacology</i> , 1981 , 75, 380-2	4.7	12
114	Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. <i>Clinical Pharmacology and Therapeutics</i> , 1981 , 30, 475-86	6.1	151
113	Diazepam kinetics in relation to age and sex. <i>Pharmacology</i> , 1981 , 23, 24-30	2.3	95
112	Diazepam interaction with antituberculosis drugs. <i>Clinical Pharmacology and Therapeutics</i> , 1981 , 29, 671-81	6.1	72
111	Noninteraction of digitoxin and quinidine. <i>New England Journal of Medicine</i> , 1980 , 303, 672-4	59.2	24
110	Entry of diazepam and its major metabolite into cerebrospinal fluid. <i>Psychopharmacology</i> , 1980 , 70, 89-92	4.7	82
109	Electron-capture GLC determination of clobazam and desmethyldiazepam in plasma. <i>Journal of Pharmaceutical Sciences</i> , 1980 , 69, 1351-2	3.9	19
108	Desmethyldiazepam kinetics in the elderly after oral prazepam. <i>Clinical Pharmacology and Therapeutics</i> , 1980 , 28, 196-202	6.1	82
107	Single- and multiple-dose kinetics of intravenous digoxin. <i>Clinical Pharmacology and Therapeutics</i> , 1980 , 28, 340-5	6.1	18
106	Effect of food on enteral absorption of quinidine. <i>Clinical Pharmacology and Therapeutics</i> , 1980 , 27, 188-93	6.1	20
105	Diazepam disposition determinants. <i>Clinical Pharmacology and Therapeutics</i> , 1980 , 27, 301-12	6.1	319
104	Reduction in lidocaine clearance during continuous infusion and by coadministration of propranolol. <i>New England Journal of Medicine</i> , 1980 , 303, 373-7	59.2	136
103	Comparative protein binding of diazepam and desmethyldiazepam. <i>Journal of Clinical Pharmacology</i> , 1980 , 20, 639-43	2.9	3

102	Entry of quinidine into cerebrospinal fluid. <i>American Heart Journal</i> , 1980 , 100, 341-6	4.9	25
101	Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans. <i>American Heart Journal</i> , 1980 , 99, 468-75	4.9	21
100	Clinical pharmacokinetics of quinidine. <i>Clinical Pharmacokinetics</i> , 1980 , 5, 150-68	6.2	89
99	Serum digoxin concentrations and subjective manifestations of toxicity. <i>Pharmacology</i> , 1980 , 20, 149-54	2.3	8
98	Pharmacokinetic and clinical implications of quinidine protein binding. <i>Journal of Pharmaceutical Sciences</i> , 1979 , 68, 466-70	3.9	53
97	Single- and multiple-dose kinetics of estazolam, a triazolo benzodiazepine. <i>Psychopharmacology</i> , 1979 , 66, 267-74	4.7	31
96	Self-rated sedation and plasma concentrations of desmethyldiazepam following single doses of clorazepate. <i>Psychopharmacology</i> , 1979 , 66, 289-90	4.7	19
95	Single- and multiple-dose kinetics of oral lorazepam in humans: the predictability of accumulation. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1979 , 7, 159-79		30
94	Effect of age and Billroth gastrectomy on absorption of desmethyldiazepam from clorazepate. <i>Clinical Pharmacology and Therapeutics</i> , 1979 , 26, 449-56	6.1	25
93	Effects of three antibiotics on theophylline kinetics. <i>Clinical Pharmacology and Therapeutics</i> , 1979 , 26, 36-40	6.1	59
92	Lorazepam kinetics in the elderly. <i>Clinical Pharmacology and Therapeutics</i> , 1979 , 26, 103-13	6.1	123
91	Chlordiazepoxide and oxazepam disposition in cirrhosis. <i>Clinical Pharmacology and Therapeutics</i> , 1979 , 26, 240-6	6.1	48
90	Single-dose kinetics of prazepam, a precursor of desmethyldiazepam. <i>Journal of Clinical Pharmacology</i> , 1979 , 19, 445-50	2.9	11
89	Clinical effects of chloral hydrate in hospitalized medical patients. <i>Journal of Clinical Pharmacology</i> , 1979 , 19, 669-74	2.9	14
88	Overdosage with pentobarbital and secobarbital: assessment of factors related to outcome. <i>Journal of Clinical Pharmacology</i> , 1979 , 19, 758-68	2.9	15
87	Reduced serum albumin concentration in the elderly: a report from the Boston Collaborative Drug Surveillance Program. <i>Journal of the American Geriatrics Society</i> , 1979 , 27, 20-2	5.6	154
86	Clinical importance of the interaction of phenytoin and isoniazid: a report from the Boston Collaborative Drug Surveillance Program. <i>Chest</i> , 1979 , 75, 356-8	5.3	79
85	Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. <i>Journal of Pharmaceutical Sciences</i> , 1979 , 68, 57-63	3.9	156

84	Benzodiazepines: some aspects of their clinical pharmacology. <i>Novartis Foundation Symposium</i> , 1979 , 141-55		4
83	Effect of a cocktail on diazepam absorption. <i>Psychopharmacology</i> , 1978 , 57, 199-203	4.7	33
82	Analysis of lorazepam and its glucuronide metabolite by electron-capture gas-liquid chromatography. <i>Biomedical Applications</i> , 1978 , 146, 311-320		76
81	Absorption of oral tetracycline in patients with Billroth-II gastrectomy. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1978 , 6, 295-303		11
80	Determination of desmethyldiazepam in plasma by electron-capture GLC: application to pharmacokinetic studies of clorazepate. <i>Journal of Pharmaceutical Sciences</i> , 1978 , 67, 427-9	3.9	20
79	Dependence, tolerance, and addiction to benzodiazepines: clinical and pharmacokinetic considerations. <i>Drug Metabolism Reviews</i> , 1978 , 8, 13-28	7	199
78	Clinical pharmacokinetics of chlordiazepoxide. <i>Clinical Pharmacokinetics</i> , 1978 , 3, 381-94	6.2	47
77	Drug interactions involving psychotropic drugs. <i>Psychosomatics</i> , 1978 , 19, 671-3, 677-81	2.6	9
76	A reevaluation of intravenous quinidine. <i>American Heart Journal</i> , 1978 , 96, 829-32	4.9	15
75	Spironolactone. <i>American Heart Journal</i> , 1978 , 96, 389-400	4.9	58
74	Dose-independent pharmacokinetics of digoxin in humans. <i>American Heart Journal</i> , 1978 , 96, 507-11	4.9	34
73	Single and multiple dose pharmacokinetics of oral quinidine sulfate and gluconate. <i>American Journal of Cardiology</i> , 1978 , 41, 770-7	3	33
72	Reduced quinidine clearance in elderly persons. <i>American Journal of Cardiology</i> , 1978 , 42, 481-5	3	78
71	Pharmacokinetics and bioavailability of digoxin capsules, solution and tablets after single and multiple doses. <i>American Journal of Cardiology</i> , 1978 , 42, 129-36	3	24
70	Prazepam and lorazepam, two new benzodiazepines. <i>New England Journal of Medicine</i> , 1978 , 299, 1342-4	39.2	35
69	Short- and long-acting oral quinidine preparations: clinical implications of pharmacokinetic differences. <i>Angiology</i> , 1978 , 29, 243-50	2.1	2
68	Clinical toxicity of theophylline in relation to cigarette smoking. A report from the Boston Collaborative Drug Surveillance Program. <i>Chest</i> , 1978 , 73, 455-9	5.3	56
67	Effect of propranolol on pharmacokinetics and acute electrocardiographic changes following intravenous quinidine in humans. <i>Pharmacology</i> , 1978 , 17, 301-6	2.3	23

66	Effect of abdominal radiation therapy on drug absorption in humans. <i>Journal of Clinical Pharmacology</i> , 1978 , 18, 388-96	2.9	11
65	Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. <i>Clinical Pharmacology and Therapeutics</i> , 1978 , 24, 308-15	6.1	54
64	Cerebrospinal fluid digoxin concentrations in humans. <i>Journal of Clinical Pharmacology</i> , 1978 , 18, 16-20	2.9	8
63	Diazepam absorption: effect of antacids and food. <i>Clinical Pharmacology and Therapeutics</i> , 1978 , 24, 600-1	6.1	62
62	Kinetics of intravenous and intramuscular morphine. <i>Clinical Pharmacology and Therapeutics</i> , 1978 , 24, 52-9	6.1	184
61	Sex differences in diazepam protein binding in patients with renal insufficiency. <i>Pharmacology</i> , 1978 , 16, 26-9	2.3	17
60	Problems with Drug Interactions in Treating Brain Disorders. <i>Psychiatric Clinics of North America</i> , 1978 , 1, 51-69	3.1	7
59	Meprobamate overdosage: a continuing problem. <i>Clinical Toxicology</i> , 1977 , 11, 501-15		20
58	Acute overdosage with benzodiazepine derivatives. <i>Clinical Pharmacology and Therapeutics</i> , 1977 , 21, 497-514	6.1	99
57	Evidence for systematic temporal variation in 24-hour urinary creatinine excretion. <i>Journal of Clinical Pharmacology</i> , 1977 , 17, 108-19	2.9	9
56	Toxicity of high-dose flurazepam in the elderly. <i>Clinical Pharmacology and Therapeutics</i> , 1977 , 21, 355-61	6.1	183
55	Clinical pharmacokinetics of lorazepam. II. Intramuscular injection. <i>Clinical Pharmacology and Therapeutics</i> , 1977 , 21, 222-30	6.1	43
54	Kinetics of intravenous chlordiazepoxide: sex differences in drug distribution. <i>Clinical Pharmacology and Therapeutics</i> , 1977 , 22, 893-903	6.1	34
53	Clinical pharmacokinetics of lorazepam. III. Intravenous injection. Preliminary results. <i>Journal of Clinical Pharmacology</i> , 1977 , 17, 490-4	2.9	28
52	Absorption and disposition of chlordiazepoxide in young and elderly male volunteers. <i>Journal of Clinical Pharmacology</i> , 1977 , 17, 709-18	2.9	86
51	Pharmacokinetics and clinical effects of amantadine in drug-induced extrapyramidal symptoms. <i>Journal of Clinical Pharmacology</i> , 1977 , 17, 704-8	2.9	27
50	Clinical pharmacokinetics of lorazepam. IV. Long-term oral administration. <i>Journal of Clinical Pharmacology</i> , 1977 , 17, 495-500	2.9	9
49	Clinical toxicity of furosemide in hospitalized patients. A report from the Boston Collaborative Drug Surveillance Program. <i>American Heart Journal</i> , 1977 , 94, 6-13	4.9	51

48	Factors influencing blood concentrations of chlordiazepoxide: a use of multiple regression analysis. <i>Psychopharmacology</i> , 1977 , 54, 277-82	4.7	16
47	Adverse reactions to practolol in hospitalized patients: a report from the Boston Collaborative Drug Surveillance Program. <i>European Journal of Clinical Pharmacology</i> , 1977 , 12, 167-70	2.8	7
46	Bioavailability of drugs: the digoxin dilemma. <i>Clinical Pharmacokinetics</i> , 1976 , 1, 36-51	6.2	57
45	Variability of 24-hour urinary creatinine excretion by normal subjects. <i>Journal of Clinical Pharmacology</i> , 1976 , 16, 321-8	2.9	108
44	Clinical use and toxicity of intravenous lidocaine. A report from the Boston Collaborative Drug Surveillance Program. <i>American Heart Journal</i> , 1976 , 92, 168-73	4.9	91
43	Assessment of methodology in single-dose studies of digoxin bioavailability. <i>Pharmacology</i> , 1976 , 14, 182-90	2.3	11
42	Kinetics of high-dose intravenous morphine in cardiac surgery patients. <i>Clinical Pharmacology and Therapeutics</i> , 1976 , 19, 752-6	6.1	35
41	Clinical pharmacokinetics of lorazepam. I. Absorption and disposition of oral ¹⁴ C-lorazepam. <i>Clinical Pharmacology and Therapeutics</i> , 1976 , 20, 329-41	6.1	66
40	Plasma and cerebrospinal fluid concentrations of chlordiazepoxide and its metabolites in surgical patients. <i>Clinical Pharmacology and Therapeutics</i> , 1976 , 20, 571-8	6.1	17
39	Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption. <i>Clinical Pharmacology and Therapeutics</i> , 1976 , 19, 234-9	6.1	42
38	Serum creatine phosphokinase concentrations after intramuscular chlordiazepoxide and its solvent. <i>Journal of Clinical Pharmacology</i> , 1976 , 16, 118-21	2.9	15
37	Digitalis. Clinical implications of new facts about an old drug. <i>Postgraduate Medicine</i> , 1976 , 59, 134-9	3.7	1
36	Intramuscular injection of drugs. <i>New England Journal of Medicine</i> , 1976 , 295, 542-6	59.2	131
35	Accidental iron poisoning in childhood. Six cases including one fatality. <i>Clinical Pediatrics</i> , 1976 , 15, 835-8	1.2	16
34	Flurazepam hydrochloride. <i>Clinical Pharmacology and Therapeutics</i> , 1975 , 17, 1-14	6.1	50
33	Role of nurse and pharmacist monitors in the Boston Collaborative Drug Surveillance Program. <i>Drug Intelligence & Clinical Pharmacy</i> , 1975 , 9, 648-54		3
32	Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1975 , 3, 181-92		107
31	Pharmacotherapy of Essential Hypertension. <i>American Journal of Health-System Pharmacy</i> , 1975 , 32, 508-517	2.2	

30	Flurazepam hydrochloride, a benzodiazepine hypnotic. <i>Annals of Internal Medicine</i> , 1975 , 83, 237-41	8	29
29	Rational Use of psychotropic drugs IV. Antidepressants. <i>American Journal of Health-System Pharmacy</i> , 1975 , 32, 59-64	2.2	
28	Chlordiazepoxide metabolism in mice following hepatic irradiation. <i>Pharmacology</i> , 1975 , 13, 248-51	2.3	4
27	Letter: Intravenous digoxin as a bioavailability standard. <i>Clinical Pharmacology and Therapeutics</i> , 1975 , 17, 117-8	6.1	4
26	Clinical pharmacokinetics (second of two parts). <i>New England Journal of Medicine</i> , 1975 , 293, 964-70	59.2	183
25	Drug therapy. Clinical Pharmacokinetics (first of two parts). <i>New England Journal of Medicine</i> , 1975 , 293, 702-5	59.2	409
24	Adverse reactions to beta-adrenergic receptor blocking drugs: a report from the Boston collaborative drug surveillance program. <i>Drugs</i> , 1974 , 7, 118-29	12.1	124
23	Comparison of one- and six-day urinary digoxin excretion in single-dose bioavailability studies. <i>Clinical Pharmacology and Therapeutics</i> , 1974 , 16, 813-6	6.1	12
22	Influence of serum digoxin concentration measurements on frequency of digitoxicity. <i>Clinical Pharmacology and Therapeutics</i> , 1974 , 16, 284-7	6.1	41
21	Bioavailability of digoxin tablets and elixir in the fasting and postprandial states. <i>Clinical Pharmacology and Therapeutics</i> , 1974 , 16, 444-8	6.1	30
20	Intravenous digoxin as a bioavailability standard: slow infusion and rapid injection. <i>Clinical Pharmacology and Therapeutics</i> , 1974 , 15, 510-3	6.1	27
19	Rational Use of Psychotropic Drugs III. Major Tranquilizers. <i>American Journal of Health-System Pharmacy</i> , 1974 , 31, 1226-1232	2.2	
18	Pharmacokinetic Determinants of the Response to Single Doses of Chlordiazepoxide. <i>American Journal of Psychiatry</i> , 1974 , 131, 1395-1397	11.9	2
17	The clinical use of procainamide. <i>American Journal of Health-System Pharmacy</i> , 1974 , 31, 889-894	2.2	
16	Rational use of psychotropic drugs. I. Hypnotics. <i>American Journal of Health-System Pharmacy</i> , 1974 , 31, 990-1000	2.2	
15	Drug therapy. Benzodiazepines (second of two parts). <i>New England Journal of Medicine</i> , 1974 , 291, 1239-43	59.2	59
14	The archaic barbiturate hypnotics. <i>New England Journal of Medicine</i> , 1974 , 291, 790-1	59.2	32
13	Slow absorption of intramuscular chlordiazepoxide. <i>New England Journal of Medicine</i> , 1974 , 291, 1116-8	59.2	44

12	Adverse reactions to propranolol in hospitalized medical patients: a report from the Boston Collaborative Drug Surveillance Program. <i>American Heart Journal</i> , 1973 , 86, 478-84	4.9	200
11	Drug therapy. Anticholinergics. <i>New England Journal of Medicine</i> , 1973 , 288, 1215-9	59.2	76
10	Evaluation of digoxin bioavailability in single-dose studies. <i>New England Journal of Medicine</i> , 1973 , 289, 651-4	59.2	98
9	Chlorpromazine and Hyperpyrexia: A Reminder That This Drug Affects the Mechanisms Which Regulate Body Temperature. <i>Clinical Pediatrics</i> , 1973 , 12, 504-505	1.2	7
8	Which drug for alcohol withdrawal?. <i>The Journal of Clinical Pharmacology and New Drugs</i> , 1972 , 12, 429-31		4
7	The clinical choice of sedative-hypnotics. <i>Annals of Internal Medicine</i> , 1972 , 77, 91-100	8	23
6	Psychopharmacologic management of anxiety in the cardiac patient. <i>Psychiatry in Medicine</i> , 1971 , 2, 55-66		2
5	Meprobamate: a study of irrational drug use. <i>American Journal of Psychiatry</i> , 1971 , 127, 1297-303	11.9	30
4	Magnesium pemoline and job performance in mentally handicapped workers. <i>Clinical Pharmacology and Therapeutics</i> , 1969 , 10, 530-3	6.1	4
3	In Vitro Approaches to Anticipating Clinical Drug Interactions31-74		1
2	Mechanisms and Consequences of DrugDrug Interactions879-917		7
1	Clinical Drug Interactions Due to Metabolic Inhibition: Prediction, Assessment, and Interpretation533-547		1